01.12.2017 | Research Article | Ausgabe 6/2017 Open Access

A multifaceted intervention to reduce guideline non-adherence among prescribing physicians in Dutch hospitals
- Zeitschrift:
- International Journal of Clinical Pharmacy > Ausgabe 6/2017
Impacts on practice
-
Pharmacotherapeutic guidelines seem to be poorly implemented in daily clinical practice in Dutch hospitals.
-
Hospital pharmacists can play a leading role in the implementation of key pharmacotherapeutic guidelines.
-
Education on guidelines and support of the prescribing physician by the hospital pharmacist are an effective way to improve guideline adherence.
Introduction
Aim of the study
Ethics approval
Methods
Study design and setting
Study population
Usual care
Intervention
Guidelines
Pharmacotherapeutic measure
|
Effectuation measurement of guideline non-adherence
|
Guideline
|
---|---|---|
1. Perioperative thrombosis prophylaxis
|
All patients undergoing surgery, with a high risk of thrombosis according to the guideline, were checked whether preventive therapy for DVT and VTE was administered
|
Diagnostics, prevention and treatment of venous thromboembolism and secondary prevention of arterial occlusive disease (guideline CBO, based on ACCP) [
25]
|
2. Perioperative bridging of antithrombotics
|
All patients undergoing surgery, using vitamin K antagonists, were checked whether perioperative bridging of antithrombotics was indicated and antithrombotics were administered according to the guideline. Bridging was indicated in case of atrial fibrillation and a CHADS
2 score > 3, recent or recurrent venous thromboembolism, thromboembolism due to thrombophilia or mechanical valve prosthesis
|
Diagnostics, prevention and treatment of venous thromboembolism and secondary prevention of arterial occlusive disease (guideline CBO, based on ACCP) [
25]
|
3. PPI added in case of use of NSAID
|
All patients with an ulcer in history and/or an age older than 70 years, were checked whether a proton pump inhibitor was added
|
NSAID use and prevention of gastric damage (guideline CBO) [
26]
|
4. Laxative added in case of use of opioid
|
All patients treated with an opioid, were checked whether a laxative was added. Patients with a stoma or with diagnosed diarrhoea were excluded
|
|
5. NSAID contraindicated in impaired renal function
|
All patients with an impaired renal function (MDRD < 30 ml/min/1.73 m
2), were checked for NSAID use
|
Dutch national G-standard [
23]
SmPC NSAID [
29]
|
6. Discontinuation of diuretics in case of radiocontrast
|
All patients who received iodinated radio-contrast and who used diuretics, were checked whether the diuretic was discontinued on the day of the test
|
Precautions for use of iodinated radio-contrast (guideline NVR) [
30]
|
7. Discontinuation of NSAID in case of radio-contrast
|
All patients who received iodinated radio-contrast and who used an NSAID, were checked whether the NSAID was discontinued on the day of the test
|
Precautions for use of iodinated radio-contrast (guideline NVR) [
30]
|
8. Discontinuation of metformin in case of radio-contrast and impaired renal function
|
All patients who received iodinated radio-contrast and had impaired renal function (MDRD < 60 ml/min/1.73 m
2) and used metformin, were checked whether metformin was discontinued on the day of the test
|
Precautions for use of iodinated radio-contrast (guideline NVR) [
30]
|
9. Perioperative antibiotics prophylaxis
|
All patients undergoing surgery, with an indication for perioperative antibiotics prophylaxis, were checked whether preventive therapy for infection was administered
|
Perioperative antibiotic prophylaxis (guideline SWAB) [
31]
|
10. Perioperative endocarditis prophylaxis
|
All patients undergoing surgery, with a high risk of endocarditis, were checked whether preventive therapy for endocarditis was administered
|
Endocarditis prophylaxis (guideline by the Netherland Heart Foundation) [
32]
|
Study endpoints
Data collection
Sample size and data analysis
Results
Usual care period
|
Intervention period
|
p value
|
|
---|---|---|---|
No. of admissions
|
1435
|
1195
|
|
No. of patients
|
1378
|
1090
|
|
Mean age of patients in years ± SD
|
63.8 ± 17.2
|
63.3 ± 17.1
|
0.406
|
Gender of patients, n (%) female
|
720 (50.2%)
|
599 (50.1%)
|
0.980
|
Department of admission
|
0.605
|
||
General surgery, n (%)
|
852 (59.4%)
|
682 (57.1%)
|
|
Orthopaedic surgery, n (%)
|
328 (22.9%)
|
294 (24.6%)
|
|
Urology, n (%)
|
255 (17.8%)
|
219 (18.3%)
|
|
Mean no. of medications the first day after admission, ± SD
|
6.9 ± 5.5
|
7.2 ± 5.8
|
0.233
|
Medication the first day after admission, n (%)
|
|||
Hypoglycemics
|
178 (12.4%)
|
156 (13.1%)
|
0.618
|
Vitamin K antagonists
|
149 (10.4%)
|
117 (9.8%)
|
0.616
|
Heparin/LMWH
|
951 (66.3%)
|
773 (64.7%)
|
0.394
|
Thrombocyte aggregation inhibitors
|
284 (19.8%)
|
238 (19.9%)
|
0.936
|
Diuretics
|
337 (23.5%)
|
287 (24.0%)
|
0.749
|
Beta blockers
|
391 (27.2%)
|
305 (25.5%)
|
0.318
|
Calcium channel blockers
|
146 (10.2%)
|
142 (11.9%)
|
0.162
|
RAS inhibitors
|
375 (26.1%)
|
317 (26.5%)
|
0.819
|
NSAIDs
|
485 (33.8%)
|
424 (35.5%)
|
0.366
|
Opioids
|
601 (41.9%)
|
491 (41.1%)
|
0.681
|
Antipsychotics
|
90 (6.3%)
|
79 (6.6%)
|
0.724
|
Mean length of stay, days ± SD
|
|||
General surgery
|
7.7 ± 9.7
|
7.0 ± 8.3
|
0.154
|
Orthopaedic surgery
|
7.6 ± 8.6
|
6.7 ± 6.5
|
0.107
|
Urology
|
4.3 ± 4.8
|
4.4 ± 4.1
|
0.798
|
MDRD eGFR of patients (ml/min/1.73 m
2), n (%)
|
(n = 1016*)
|
(n = 836*)
|
0.476
|
< 10
|
4 (0.4%)
|
1 (0.1%)
|
|
10–30
|
43 (4.2%)
|
39 (4.7%)
|
|
30–60
|
227 (22.3%)
|
203 (24.3%)
|
|
> 60
|
742 (73.0%)
|
593 (70.9%)
|
Usual care period (n = 1435)
|
Intervention period (n = 1195)
|
Odds ratios and confidence intervals
|
||
---|---|---|---|---|
Non-adherence
|
Non-adherence
|
OR
|
95% CI
|
|
1. Perioperative thrombosis prophylaxis if indicated?
|
22/590 (3.7%)
|
10/490 (2.0%)
|
0.54
|
0.25–1.15
|
2. Perioperative bridging of antithrombotics if indicated?
|
2/48 (4.2%)
|
2/46 (4.3%)
|
1.05
|
0.14–7.75
|
3. In case of NSAID use, ppi added if indicated?
|
5/101 (5.0%)
|
3/83 (3.6%)
|
0.72
|
0.17–3.11
|
4. In case of opioid use, laxative added if indicated?
|
154/296 (52%)
|
62/190 (32.6%)
|
0.45
b
|
0.31–0.65
|
5. In case of impaired renal function (MDRD < 30), no use of NSAID?
|
8/50 (16.0%)
|
4/40 (10.0%)
|
0.54
|
0.15–1.94
|
6. In case of radiocontrast, diuretics discontinued?
|
16/23 (69.6%)
|
20/29 (69.0%)
|
0.97
|
0.30–3.18
|
7. In case of radiocontrast, NSAID discontinued?
|
17/25 (68.0%)
|
15/20 (75.0%)
|
1.41
|
0.38–5.26
|
8. In case of radiocontrast and MDRD < 60, metformin discontinued?
|
2/3 (66.7%)
|
2/2 (100.0%)
|
0.33
|
0.01-12.79
|
9. Perioperative antibiotics prophylaxis, if indicated?
|
136/832 (16.3%)
|
93/661 (14.1%)
|
0.84
|
0.63–1.12
|
10. Perioperative endocarditis prophylaxis, if indicated?
|
6/8 (75%)
|
0/3 (0%)
|
0.05
|
0.00–1.50
|
Overall non-adherence
|
332/1089 (30.5%)
|
193/886 (21.8%)
|
0.64
b
|
0.52–0.78
|
0.61
a,b
|
0.49–0.76
|